

HALF-YEAR REPORT
FEBRUARY TO JULY 2024




CONTENTS


2	The first half-year at a glance
3	Interim group management report
3	Business and economic environment
5	Risks and opportunities
5	Forecast
6	Interim condensed consolidated financial statements
7	Consolidated income statement
7	Consolidated statement of comprehensive income
8	Consolidated statement of financial position
9	Consolidated statement of cash flows
10	Consolidated statement of changes in equity
11	Notes to the interim condensed consolidated financial statements
20	Financial calendar 2024/Imprint

This interactive PDF is optimised for use with Adobe Acrobat. Linked tables of contents ensure easy navigation. In addition, the following function buttons can be used:


 Main table of contents

 Last page viewed

 Search

 Previous page

 Next page

 Page reference

THE FIRST HALF-YEAR AT A GLANCE

Key figures of PHOENIX Pharmahandel GmbH & Co KG (consolidated) in EUR m	1st half-year 2023/24	1st half-year 2024/25
Total operating performance	27,856.3	29,595.8
Revenue	23,209.1	24,402.5
Total income	2,307.5	2,491.5
EBITDA before significant one-off effects	425.7	549.9
EBITDA	412.3	562.2
EBIT	209.5	345.5
Profit before tax before significant one-off effects	147.5	261.2
Profit before tax	134.1	273.5
Profit after tax	89.9	209.3

		31 July 2023 ¹⁾	31 January 2024	31 July 2024
Equity	in EUR m	3,528.5	3,644.5	3,823.7
Equity ratio	in %	25.8	25.5	25.7
Net debt	in EUR m	3,128.1	2,659.2	3,123.8

¹⁾ The 31 January 2023 figures were restated due to the finalisation of a purchase price allocation.

- Total operating performance and revenue have increased again
- EBITDA above previous year
- Successful issuance of a EUR 500 million corporate bond

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity
Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint

INTERIM GROUP MANAGEMENT REPORT

BUSINESS AND ECONOMIC ENVIRONMENT

Development of the market

The European economy only grew slightly in the second quarter of 2024. In the eurozone, seasonally adjusted GDP increased by 0.6% in the second quarter of 2024 compared to the prior year's second quarter. In Germany, the seasonally and calendar-adjusted GDP slightly decreased by 0.1% compared to the second quarter of 2024.

Overall, the European pharmaceutical markets continued their moderate growth trend in the first half-year of 2024. The German pharmaceutical market also showed growth. The total turnover of the German wholesale pharmaceutical market grew by 4.5% from January to July 2024 compared to the same period of the prior year. The increase was mainly due to higher prescription pharmaceutical revenues. Market growth was also noted in various foreign markets of PHOENIX.

In total, PHOENIX continued its positive development in the European market environment.

Acquisitions

In the first half-year of 2024/25, business combinations led to a cash outflow of EUR 46.9 million (comparative period: EUR 76.9 million). The acquisitions mostly pertained to pharmacies in several countries.

Results of operations

Compared with the half-year of fiscal year 2023/24, total operating performance increased by 6.2% to EUR 29,595.8 million in the first six months of 2024/25. This comprises revenue and handled volume. Adjusted for foreign exchange rate effects, total operating performance grew by 6.3%. Revenue grew by EUR 1,193.4 million (5.1%) to EUR 24,402.5 million (comparative period: EUR 23,209.1 million). Adjusted for foreign exchange rate effects, revenue grew by 5.3%.

Gross profit increased by EUR 145.4 million to EUR 2,422.3 million. The gross profit margin came to 9.9% (comparative period: 9.8%).

Personnel expenses increased from EUR 1,191.1 million by 1.7% to EUR 1,210.8 million. This was mainly due to the impact of collective wage increases, acquisitions, and the growth in business. In relation to revenue, personnel expenses came to 5.0% (comparative period: 5.1%).

Other expenses increased by EUR 28.6 million to EUR 731.3 million. In the comparative period, other expenses include a loss on the deconsolidation of the wholesale activities in Switzerland of EUR 13.4 million. In relation to revenue, other expenses came to 3.0% (comparative period: 3.0%).

Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased from EUR 412.3 million to EUR 562.2 million. This figure includes a gain from the revaluation of an investment in connection with a business combination achieved in stages of EUR 12.3 million. Adjusted for this effect and the deconsolidation loss in Switzerland in the comparative period, EBITDA came to EUR 549.9 million and was EUR 124.2 million higher than the prior year's amount.

Depreciation and amortisation came to EUR 216.7 million (including EUR 24.6 million related to purchase price allocation effects; comparative period: EUR 25.8 million) and were above the prior year's level (EUR 202.9 million).

The financial result improved by EUR 3.4 million from EUR –75.4 million in the comparative period to EUR –72.0 million. The decrease is due to a premature repayment of bond certificates below their carrying amount and the negative impact of the revaluation of a settlement obligation to minority shareholders of McKesson Europe AG in the comparative period.

Profit before tax increased from EUR 134.1 million to EUR 273.5 million. Adjusted for the gain from the revaluation of an investment in connection with a business combination achieved in stages, as well as the deconsolidation loss in Switzerland in the comparative period, profit before tax increased by EUR 113.7 million to EUR 261.2 million.

The first half-year at a glance

Interim group management report

Business and economic environment

Risks and opportunities

Forecast

Interim condensed consolidated financial statements

Consolidated income statement

Consolidated statement of comprehensive income

Consolidated statement of financial position

Consolidated statement of cash flows

Consolidated statement of changes in equity

Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint

The effective tax rate in the first half-year of 2024/25 came to 23.5% and was 33.0% in the comparative period.

Profit after tax came to EUR 209.3 million (comparative period: EUR 89.9 million).

Net assets

The group's total assets increased slightly by 4.0% to EUR 14,885.3 million compared with 31 January 2024. The currency translation difference on the total assets, which is presented in the statement of changes in equity, amounts to EUR – 136.7 million (31 January 2024: EUR – 124.1 million).


Non-current assets slightly increased from EUR 4,815.3 million as of 31 January 2024 to EUR 4,854.6 million. The intangible assets contain goodwill in the amount of EUR 1,517.9 million (31 January 2024: EUR 1,437.8 million).

Inventories increased compared with 31 January 2024 by EUR 188.9 million to EUR 4,015.1 million.

Trade receivables increased by 3.2% to EUR 4,964.8 million. As of 31 July 2024, receivables of EUR 111.5 million (31 January 2024: EUR 111.1 million) had been sold under ABS and factoring programmes that are not accounted for in the statement of financial position. Under ABS and factoring programmes that are accounted for only to the extent of the continuing involvement, receivables of EUR 210.1 million had been sold as of 31 July 2024 (31 January 2024: EUR 212.0 million). The group's continuing involvement came to EUR 8.4 million (31 January 2024: EUR 8.5 million).

Other current financial assets increased from EUR 111.7 million as of 31 January 2024 to EUR 144.2 million and mainly include receivables from PHOENIX Pharma SE of EUR 52.8 million (31 January 2024: EUR 2.4 million), loans granted to customers of EUR 24.2 million (31 January 2024: EUR 35.4 million), as well as receivables from factoring and ABS transactions of EUR 38.5 million (31 January 2024: EUR 29.6 million).

Other current assets increased from EUR 265.8 million as of 31 January 2024 to EUR 354.3 million, among others, due to higher receivables from other taxes.

The change in cash and cash equivalents is presented in the  consolidated statement of cash flows on p. 9.

Financial position

Equity increased by EUR 179.2 million compared to 31 January 2024. The equity ratio as of 31 July 2024 came to 25.7% (31 January 2024: 25.5%).

Cash flow from operating activities came to EUR – 154.9 million (comparative period: EUR – 51.7 million). This is mainly due to a higher increase in trade working capital of EUR 207.7 million. The increased profit after tax had a positive impact on the cash flow from operating activities. Cash flow from investing activities came to EUR – 119.3 million and was EUR – 182.3 million in the comparative period.

Non-current financial liabilities came to EUR 1,894.3 million (31 January 2024: EUR 1,703.7 million). This item includes lease liabilities according to IFRS 16 of EUR 801.3 million (31 January 2024: EUR 806.8 million). Beyond that, non-current financial liabilities contain, among others, bonds of EUR 494.3 million (31 January 2024: EUR 398.5 million) and promissory notes of EUR 332.0 million (31 January 2024: EUR 332.0 million).

Current financial liabilities came to EUR 1,479.0 million (31 January 2024: EUR 1,117.5 million) and include lease liabilities according to IFRS 16 of EUR 177.7 million (31 January 2024: EUR 173.0 million). Beyond that, current financial liabilities contain, among others, bonds of EUR 185.4 million (31 January 2024: EUR 0.0 million), liabilities to banks of EUR 489.1 million (31 January 2024: EUR 361.1 million), liabilities from ABS and factoring agreements in the amount of EUR 325.6 million (31 January 2024: EUR 336.8 million), as well as other loans amounting to EUR 251.3 million (31 January 2024: EUR 212.9 million).

The first half-year at a glance

Interim group management report

Business and economic environment

Risks and opportunities

Forecast

Interim condensed consolidated financial statements

Consolidated income statement

Consolidated statement of comprehensive income

Consolidated statement of financial position

Consolidated statement of cash flows

Consolidated statement of changes in equity

Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint

According to the calculation below, net debt increased by EUR 464.6 million compared to 31 January 2024 to EUR 3,123.8 million.

EUR k	31 January 2024	31 July 2024	Change	Change in %
+ Financial liabilities (non-current)	1,703,673	1,894,292	150,758	8.8
./. Derivative financial instruments (non-current)	-1	-1	0	0.0
+ Financial liabilities (current)	1,117,475	1,479,047	401,433	35.9
./. Derivative financial instruments (current)	-4,214	-3,116	1,098	-26.1
./. Cash and cash equivalents	-442,740	-51,592	391,148	-88.3
+ Receivables sold in the course of ABS and factoring transactions	314,626	-156,290	-470,916	-149.7
./. Factoring receivables	-28,765	-37,688	-8,923	31.0
./. Receivables from ABS programmes	-866	-840	26	-3.0
Net debt	2,659,188	3,123,812	464,624	17.5

Trade payables decreased by EUR 100.8 million to EUR 6,420.0 million.

Overall, PHOENIX was able to underline its position in the first half-year of 2024/25 as a leading healthcare provider in Europe.

RISKS AND OPPORTUNITIES

PHOENIX has comprehensive planning, approval and reporting structures, as well as an early warning system, which we use to identify, assess, and monitor our opportunities and risks. The opportunities and risks of significance to us are presented extensively in our annual report for fiscal year 2023/24.

www.phoenixgroup.eu/en/publications/financial-reports

The risks and opportunities presented in that report are still essentially relevant.

FORECAST

For fiscal year 2024/25, PHOENIX expects to further expand its market position in Europe through organic growth, acquisitions and efficiency improvements and thereby increase revenue slightly above the level of growth of the European pharmaceutical markets. We expect revenue to grow in nearly all markets in which we are present.

We forecast profit before tax to increase noticeably in fiscal year 2024/25 compared to the prior year.

We also expect a slight increase in the equity ratio.

The first half-year at a glance

Interim group management report

[Business and economic environment](#)
[Risks and opportunities](#)
[Forecast](#)

Interim condensed consolidated financial statements

[Consolidated income statement](#)
[Consolidated statement of comprehensive income](#)
[Consolidated statement of financial position](#)
[Consolidated statement of cash flows](#)
[Consolidated statement of changes in equity](#)
[Notes to the interim condensed consolidated financial statements](#)

[Financial calendar 2024/Imprint](#)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2024/2025

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

**Interim condensed consolidated
financial statements**

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity
Notes to the interim condensed
consolidated financial statements

Financial calendar 2024/Imprint

CONSOLIDATED INCOME STATEMENT

for the first half-year of 2024/25

EUR k	2nd quarter 2023/24	2nd quarter 2024/25	1st half-year 2023/24	1st half-year 2024/25
Revenue	11,815,955	12,271,992	23,209,123	24,402,517
Cost of purchased goods and services	-10,669,912	-11,054,420	-20,932,173	-21,980,207
Gross profit	1,146,043	1,217,572	2,276,950	2,422,310
Other operating income	13,858	48,244	30,593	69,184
Personnel expenses	-601,815	-605,361	-1,191,051	-1,210,840
Other operating expenses	-346,825	-373,821	-702,756	-731,341
Results from associates and joint ventures	-686	12,138	-1,496	12,763
Results from other investments	7	51	81	130
Earnings before interest, taxes, depreciation and amortisation (EBITDA)	210,582	298,823	412,321	562,206
Amortisation of intangible assets and depreciation of property, plant and equipment	-102,438	-109,494	-202,860	-216,720
Earnings before interest and taxes (EBIT)	108,144	189,329	209,461	345,486
Interest income	3,340	5,405	7,983	10,041
Interest expenses	-42,024	-43,539	-74,554	-83,785
Other financial result	-674	3,187	-8,785	1,768
Financial result	-39,358	-34,947	-75,356	-71,976
Profit before tax	68,786	154,382	134,105	273,510
Income taxes	-22,634	-36,583	-44,255	-64,221
Profit after tax	46,152	117,799	89,850	209,289
thereof attributable to non-controlling interests	4,311	3,879	8,633	8,408
thereof attributable to the shareholders of the parent company	41,841	113,920	81,217	200,881

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the first half-year of 2024/25

EUR k	2nd quarter 2023/24	2nd quarter 2024/25	1st half-year 2023/24	1st half-year 2024/25
Profit after tax	46,152	117,799	89,850	209,289
Items not reclassified to the income statement				
Remeasurement of defined benefit plans	-3,357	-112	-3,116	430
Items that may be subsequently reclassified to the income statement				
Currency translation differences	-4,144	1,292	-9,826	-12,658
Other comprehensive income, net of taxes	-7,501	1,180	-12,942	-12,228
Total comprehensive income	38,651	118,979	76,908	197,061
thereof attributable to non-controlling interests	4,221	3,841	8,883	8,366
thereof attributable to the shareholders of the parent company	34,430	115,138	68,025	188,695

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

[Consolidated income statement](#)

[Consolidated statement
of comprehensive income](#)

Consolidated statement
of financial position

Consolidated statement of cash flows

Consolidated statement
of changes in equity

Notes to the interim condensed
consolidated financial statements

Financial calendar 2024/Imprint

CONSOLIDATED STATEMENT OF FINANCIAL POSITION as of 31 July 2024

ASSETS

EUR k	31 Jan 2024	31 July 2024
Non-current assets		
Intangible assets	2,212,401	2,295,798
Property, plant and equipment	2,287,157	2,243,453
Investment property	3,833	3,814
Investments in associates and joint ventures	38,593	31,551
Trade receivables	11,552	18,111
Other financial assets	110,850	104,963
Deferred tax assets	150,889	156,867
Income tax receivables	68	61
	4,815,343	4,854,618
Current assets		
Inventories	3,826,193	4,015,099
Trade receivables	4,800,419	4,946,737
Income tax receivables	33,590	46,727
Other financial assets	111,661	144,204
Other assets	265,836	354,288
Cash and cash equivalents	442,740	521,074
	9,480,439	10,028,129
Non-current assets held for sale	13,366	2,540
Total assets	14,309,148	14,885,287

EQUITY AND LIABILITIES

EUR k	31 Jan 2024	31 July 2024
Equity		
Unlimited and limited partners' capital	851,000	851,000
Reserves	3,017,595	3,211,483
Accumulated other comprehensive income	-340,350	-352,536
Equity attributable to the shareholders of the parent company	3,528,245	3,709,947
Non-controlling interests	116,296	113,777
	3,644,541	3,823,724
Non-current liabilities		
Financial liabilities	1,703,673	1,894,292
Trade payables	222	301
Provisions for pensions and similar obligations	316,967	303,016
Other non-current provisions	17,675	30,489
Deferred tax liabilities	243,905	251,350
Income tax liabilities	5	5
Other non-current liabilities	5,623	6,327
	2,288,070	2,485,780
Current liabilities		
Financial liabilities	1,117,475	1,479,047
Trade payables	6,520,628	6,419,729
Other provisions	81,253	63,341
Income tax liabilities	73,914	82,205
Other liabilities	575,803	530,754
	8,369,073	8,575,076
Liabilities directly associated with assets held for sale	7,464	707
Total equity and liabilities	14,309,148	14,885,287

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
[Consolidated statement of financial position](#)
Consolidated statement of cash flows
Consolidated statement of changes in equity
Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint



CONSOLIDATED STATEMENT OF CASH FLOWS for the first half-year of 2024/25

EUR k	31 July 2023	31 July 2024
Profit after tax	89,850	209,289
Income taxes	44,255	64,221
Profit before income taxes	134,105	273,510
Adjustments for:		
Interest expenses and interest income	66,571	73,744
Amortisation/depreciation/impairment/write-ups of intangible assets, property, plant and equipment and investment property	202,860	216,720
Result from associates and other investments	1,415	-12,893
Net result from the disposal of assets related to investing activities	6,830	-2,711
Other non-cash expense and income	109,944	121,176
	521,725	669,546
Interest paid	-57,643	-76,935
Interest received	7,448	10,088
Income taxes paid	-59,979	-62,489
Dividends received	245	306
Cash flow before change in assets and liabilities	411,796	540,516
Changes in assets and liabilities, net of effects of changes in the scope of consolidation and other non-cash transactions:		
Change in non-current provisions	-15,364	-22,935
Cash flow before change in operating assets and liabilities	396,432	517,581
Change in inventories	-286,513	-206,234
Change in trade receivables	-129,443	-233,649
Change in trade payables	208,500	24,753
	-207,456	-415,130
Change in other assets and liabilities not related to investing or financing activities	-240,689	-257,372
Change in operating assets and liabilities	-448,145	-672,502
Cash flow from operating activities	-51,713	-154,921
Acquisition of consolidated companies and business units, net of cash acquired	-76,936	-46,863
Capital expenditures for intangible assets, property, plant and equipment, and investment property	-91,270	-75,788
Investment in other financial assets and non-current assets	-36,470	-4,019
Cash outflows for investments	-204,676	-126,670

EUR k	31 July 2023	31 July 2024
Cash received from the sale of consolidated companies and business units, net of cash disposed	177	-3,455
Cash received from disposal of intangible assets, property, plant and equipment and investment property	18,884	10,719
Proceeds from other financial assets and non-current assets	3,297	113
Cash inflows from realised investments and divestments	22,358	7,377
Cash flow from investing activities	-182,318	-119,293
Cash available for financing activities	-234,031	-274,215
Capital contribution from/repayment to non-controlling interests	-339	0
Distributions from reserves	0	-23,615
Acquisition of additional shares in already consolidated subsidiaries	-26	-3,318
Proceeds from disposal of interests in subsidiaries without loss of control	0	100
Dividends paid to non-controlling interests	-41,322	-6,518
Proceeds from bond issuance and bank loans	7,220	861,077
Repayment of bonds and bank loans	-72,884	-485,158
Change in bank loans which have a maturity period of 3 months or less	384,668	110,078
Proceeds from the issue of loans from shareholders in the parent company	30,400	0
Repayment of loans from shareholders in the parent company	-100	-25,705
Change in ABS/Factoring	-48,094	-20,920
Change in finance lease	-84,047	-92,508
Change in other financial liabilities	-229,545	39,756
Cash flow from financing activities	-54,069	353,269
Changes in cash and cash equivalents	-288,100	79,055
Effect of exchange rate changes on cash and cash equivalents	626	-661
Cash and cash equivalents at the beginning of the period	430,015	442,680
Cash and cash equivalents at the end of the period	142,541	521,074
Cash and cash equivalents presented in the balance sheet at the end of the period	142,541	521,074

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
[Consolidated statement of cash flows](#)
Consolidated statement of changes in equity
Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY for the first half-year of 2024/25

EUR k	Unlimited and limited partners' capital	Reserves	Currency translation differences	Remeasurement of defined benefit plans	Equity attributable to the shareholders of the parent company	Non-controlling interests	Total equity
1 February 2023	851,000	2,836,342	-106,883	-188,060	3,392,399	115,560	3,507,959
Adjustment due to the update of a preliminary purchase price allocation		-12,833			-12,833	-21	-12,854
1 February 2023 adjusted	851,000	2,823,509	-106,883	-188,060	3,379,566	115,539	3,495,105
Profit after tax		81,217			81,217	8,633	89,850
Accumulated other comprehensive income			-10,076	-3,116	-13,192	250	-12,942
Total comprehensive income, net of tax		81,217	-10,076	-3,116	68,025	8,883	76,908
Changes in the basis of consolidation		4,510		-4,510	0	-16	-16
Changes in the interest of consolidated companies		-5			-5	-7	-12
Dividends					0	-9,943	-9,943
Other transactions with owners		-35,000			-35,000	0	-35,000
Other changes in equity		1,483			1,483	-15	1,468
31 July 2023	851,000	2,875,714	-116,959	-195,686	3,414,069	114,441	3,528,510
1 February 2024	851,000	3,017,595	-124,074	-216,276	3,528,245	116,296	3,644,541
Profit after tax		200,881			200,881	8,408	209,289
Accumulated other comprehensive income			-12,616	430	-12,186	-42	-12,228
Total comprehensive income, net of tax		200,881	-12,616	430	188,695	8,366	197,061
Changes in basis of consolidation		-4,289			-4,289	83	-4,206
Changes in the interest of consolidated companies		-276			-276	-3,633	-3,909
Dividends					0	-10,056	-10,056
Other transactions with owners		186			186	0	186
Other changes in equity		-2,614			-2,614	2,721	107
31 July 2024	851,000	3,211,483	-136,690	-215,846	3,709,947	113,777	3,823,724

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
[Consolidated statement of changes in equity](#)
Notes to the interim condensed consolidated financial statements

Financial calendar 2024/Imprint

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

as of 31 July 2024

The company

PHOENIX Pharmahandel GmbH & Co KG, Mannheim, ("PHOENIX") is a European healthcare provider and pharmaceuticals distribution group. PHOENIX has business activities in 29 European countries. In several countries, PHOENIX also operates its own pharmacy chains. The registered office is located in Mannheim, Germany.

Basis of presentation

The interim condensed consolidated financial statements of PHOENIX as of 31 July 2024 are prepared on the basis of IAS 34 "Interim Financial Reporting", observing all International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB), London, and mandatory in the EU as of 31 July 2024, as well as all mandatory interpretations of the International Financial Reporting Standards Interpretation Committee (IFRS IC).

The interim condensed consolidated financial statements as of 31 July 2024 of PHOENIX were released for publication by the management of PHOENIX Pharmahandel GmbH & Co KG on 12 September 2024.

Significant accounting policies

The accounting policies used to prepare the interim condensed consolidated financial statements are – except where financial reporting standards have been applied for the first time in 2024/25 – essentially consistent with those used in the consolidated financial statements as of 31 January 2024.

In fiscal year 2024/25, PHOENIX applied the following standards and interpretations that are mandatory for fiscal year 2024/25 for the first time:

Standard/Interpretation	Title	Effects on the interim condensed consolidated financial statements
Amendments to IAS 1	Classification of Liabilities as Current or Non-current – Deferral of Effective Date and Non-current Liabilities with Covenants	No effects
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements – Reverse Factoring	No effects
Amendments to IFRS 16	Lease Liability in a Sale and Leaseback	No effects

Business combinations

The business combinations carried out in the first six months of 2024/25 are explained below. Purchase accounting is performed in accordance with the acquisition method pursuant to IFRS 3 "Business Combinations".

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Business acquisitions in fiscal year 2024/25

The table below shows a summary of the fair values of acquisitions:

EUR k	Pharmacy Chain Ireland	Other	Total
Cash and cash equivalents	52,450	9,391	61,841
Non-controlling interests	0	18,692	18,692
Acquisition-date fair value of previously held equity interest	0	18,661	18,661
Total cost	52,450	46,744	99,194
Intangible assets	0	20,875	20,875
Other non-current assets	3,045	398	3,443
Inventories	7,397	846	8,243
Trade receivables	538	2,743	3,281
Cash and cash equivalents	5,732	5,081	10,813
Other current assets	4,903	42	4,945
Provisions for pensions and similar obligations	0	0	0
Other non-current provisions	0	0	0
Non-current financial liabilities	0	0	0
Deferred tax liabilities	0	2,461	2,461
Other non-current liabilities	0	0	0
Other provisions	0	810	810
Current financial liabilities	20,825	217	21,042
Trade payables	9,002	3,527	12,529
Income tax liabilities	0	0	0
Other liabilities	3,687	142	3,829
Net assets acquired	- 11,899	22,828	10,929
Bargain purchase	0	0	0
Goodwill	64,349	23,916	88,265

Pharmacy Chain Ireland

On 20 October 2023, PHOENIX signed an agreement to acquire all shares in a pharmacy chain in Ireland. At the end of April 2024, the Irish Competition Authority approved the transaction, which took effect on 30 April 2024. The company operates 32 pharmacy locations.

Since its inclusion in the consolidated financial statements for fiscal year 2024/25, the net profit of the pharmacy chain in Ireland has been EUR 4,256k and revenue has amounted to EUR 17,538k. If the acquisition date had been at the beginning of this reporting period, the revenue of the pharmacy chain in Ireland would have been EUR 35,075k, the net profit for the period would have been EUR 8,513k.

The purchase price allocation takes into account all the information about facts and circumstances as of the acquisition date that was available until the preparation of these financial statements. If further facts or circumstances become known within the 12-month measurement period in accordance with IFRS 3, the purchase price allocation is adjusted accordingly.

Other business combinations

In fiscal year 2024/25, the cumulative profit after tax of the acquirees came to EUR - 879k and revenue to EUR 7,429k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, accumulated revenue for the period came to EUR 17,184k. Assuming that the acquisition date coincides with the beginning of the reporting period for all business combinations, the accumulated profit after tax came to EUR - 998k.

In the first six months of 2024/25, the group acquired mainly further pharmacies that are individually immaterial.

The goodwill arising from those acquisitions was allocated to the cash-generating units Germany (EUR 14,917k), Czech Republic (EUR 7,334k), Slovakia (EUR 1,031k) and Norway (EUR 634k) and is recorded in the local functional currencies (EUR, CZK and NOK).

Non-controlling interests were recognised at the proportionate identifiable net assets in the acquirees.

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Other business acquisitions include contingent consideration of EUR 353k (maximum amount expected).

The purchase price allocation takes into account all the information about facts and circumstances as of the acquisition date that was available until the preparation of these financial statements. If further facts or circumstances become known within the 12-month measurement period in accordance with IFRS 3, the purchase price allocation is adjusted accordingly.

Revenue

The tables below show a breakdown of revenue within the meaning of IFRS 15 based on the type of goods and services:

1st half-year 2024/25	Trade revenue	Revenue from commissions	Distribution fees and consignment warehouse fees	Other logistic services	Other services	Other revenue	Revenue within the meaning of IFRS 15
EUR k							
Gross revenue	24,876,187	53,229	79,953	28,430	287,438	212,101	25,537,338
Sales deductions	-1,133,671	0	0	0	0	-9,834	-1,143,505
Revenue	23,742,516	53,229	79,953	28,430	287,438	202,267	24,393,833
thereof satisfaction of performance obligation at a point in time	23,742,516	48,754	74,346	27,461	273,714	156,738	24,323,529
thereof satisfaction of performance obligation over time	0	4,475	5,607	969	13,724	45,529	70,304

Total revenue for the first six months in fiscal year 2024/25 amounts to EUR 24,402,517k and includes revenue from leases of EUR 8,684k.

1st half-year 2023/24	Trade revenue	Revenue from commissions	Distribution fees and consignment warehouse fees	Other logistic services	Other services	Other revenue	Revenue within the meaning of IFRS 15
EUR k							
Gross revenue	23,577,982	65,429	62,460	30,906	266,854	206,740	24,210,371
Sales deductions	-1,010,476	0	-21	0	0	-1	-1,010,498
Revenue	22,567,506	65,429	62,439	30,906	266,854	206,739	23,199,873
thereof satisfaction of performance obligation at a point in time	22,567,506	61,294	57,064	29,878	255,003	163,993	23,134,738
thereof satisfaction of performance obligation over time	0	4,135	5,375	1,028	11,851	42,746	65,135

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity
[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Other operating expenses

Other operating expenses contain expenses in connection with ABS and factoring programmes of EUR 953k (comparative period: EUR 831k).

Financial result

EUR k	1st half-year 2023/24	1st half-year 2024/25
Interest income	7,983	10,041
Interest expenses	-74,554	-83,785
Other financial result	-8,785	1,768
Financial result	-75,356	-71,976

Interest income includes interest from customers of EUR 6,808k (comparative period: EUR 4,529k).

The other financial result includes exchange rate gains of EUR 11,277k (comparative period: EUR 9,545k) and exchange rate losses of EUR 5,029k (comparative period: EUR 7,585k). Changes in the market value of derivatives gave rise to income of EUR 18,946k (comparative period: EUR 32,990k) and expenses of EUR 26,003k (comparative period: EUR 37,511k).

Other assets and other liabilities

EUR k	31 Jan 2024	31 July 2024
Prepayments	91,760	128,135
Tax claims – VAT and other taxes	89,075	142,865
Sundry other assets	85,001	83,288
Other assets	265,836	354,288

EUR k	31 Jan 2024	31 July 2024
VAT and other tax liabilities	176,513	177,555
Personnel liabilities	298,054	247,006
Liabilities relating to social security/similar charges	65,431	61,257
Contract liabilities (IFRS 15)	10,091	18,762
Sundry other liabilities	25,714	26,174
Other liabilities	575,803	530,754

Other financial assets and other financial liabilities

The table below presents the non-current financial assets:

EUR k	31 Jan 2024	31 July 2024
Trade receivables, non-current	11,552	18,111
Other financial assets		
Equity and debt instruments	75,753	70,602
Other loans	8,682	11,466
Lease receivables	26,110	22,589
Other non-current financial assets	305	306
	110,850	104,963

The table below presents the current financial assets:

EUR k	31 Jan 2024	31 July 2024
Trade receivables	4,800,419	4,946,737
Other financial assets		
Loans to and receivables from associates	1,752	1,246
Other loans	35,359	24,207
Derivative financial instruments	2,214	2,169
Lease receivables	12,046	10,904
ABS-/Factoring receivables	29,631	38,528
Other current financial assets	30,659	67,150
	111,661	144,204

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

The receivables from ABS and factoring transactions as of 31 July 2024 are presented below:

EUR k	31 Jan 2024	31 July 2024
Transferred but only partly derecognised receivables		
Receivables not derecognised in accordance with IFRS 9		
Volume of receivables	429,334	429,083
Financial liabilities	327,785	316,753
Continuing involvement		
Volume of receivables	212,039	210,072
Continuing involvement	8,513	8,405
Financial liabilities	8,967	8,854
Transferred and fully derecognised receivables		
Volume of receivables	111,100	111,525
Retentions of title	29,631	38,528

At the reporting date, financial liabilities were divided into non-current and current liabilities as follows:

EUR k	31 Jan 2024	31 July 2024
Financial liabilities (non-current)		
Liabilities to banks	470,014	570,201
Bonds	398,481	494,306
Loans	35	31
Liabilities to related parties	20,000	20,000
Lease liabilities	806,768	801,257
Other financial liabilities	8,375	8,497
	1,703,673	1,894,292

EUR k	31 Jan 2024	31 July 2024
Financial liabilities (current)		
Liabilities to banks	361,150	489,124
Bonds	0	185,425
Loans	212,898	251,336
Liabilities to associates and related parties	4,242	307
ABS and factoring liabilities	336,752	325,607
Lease liabilities	172,988	177,701
Other financial liabilities	29,445	49,547
	1,117,475	1,479,047

In connection with the loan agreements, it was agreed to comply with certain financial covenants, all of which were met in the first six months of 2024/25.

Other financial liabilities (non-current) contain non-current derivative financial instruments of EUR 1k (31 January 2024: EUR 1k).

Other financial liabilities (current) contain current derivative financial instruments of EUR 3,116k (31 January 2024: EUR 4,214k).

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Information on financial instruments

The items in the statement of financial position for financial instruments are assigned to classes and categories.

The carrying amounts for each category and class of financial assets, and the fair values for each class are presented in the following table:

31 July 2024	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised cost	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Assets					
Equity and debt instruments	0	70,602	0	70,602	70,602
Trade receivables	4,535,765	429,083	0	4,964,848	4,964,848
Loans to and receivables from associates or related parties	1,246	0	0	1,246	1,246
Other loans	35,673	0	0	35,673	34,457
Derivative financial assets without hedge accounting	0	2,169	0	2,169	2,169
Other financial assets	105,983	0	0	105,983	105,983
Lease receivables	0	0	33,494	33,494	33,494
Cash and cash equivalents	521,074	0	0	521,074	521,074

31 January 2024	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised cost	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Assets					
Equity and debt instruments	0	75,753	0	75,753	75,753
Trade receivables	4,382,637	429,334	0	4,811,971	4,811,971
Loans to and receivables from associates or related parties	1,752	0	0	1,752	1,752
Other loans	44,041	0	0	44,041	42,819
Derivative financial assets without hedge accounting	0	2,214	0	2,214	2,214
Other financial assets	60,595	0	0	60,595	60,595
Lease receivables	0	0	38,156	38,156	38,156
Cash and cash equivalents	442,740	0	0	442,740	442,740

Equity and debt instruments primarily contain shares in unlisted entities and participations in limited partnerships. Shares in listed entities are measured at the quoted price determined as of the reporting date. For other equity and debt instruments, the fair value is determined using a multiplier method (revenue multiple, level 3). This method uses individually derived multipliers between 0.70 and 1.10 (31 January 2024: between 0.70 and 1.10). A 10% increase in the multipliers would increase the value by EUR 7,886k (31 January 2024: EUR 7,886k); a 10% decrease in the multipliers would decrease the value by EUR 7,805k (31 January 2024: EUR 7,805k).

Derivatives are recognised at their fair values (level 2).

Due to the short-term maturities of cash and cash equivalents, trade receivables, and other current financial assets, their carrying amounts generally approximate the fair values at the reporting date (level 2).

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity
[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

The fair value of loans to and receivables from associates or related entities, other loans, held-to-maturity financial assets and other non-current financial assets due after more than one year correspond to the net present value of the payments related to the assets based on the current interest rate parameters and yield curves (level 2).

The carrying amounts for each category and class of financial liabilities and the fair values for each class are presented in the following table:

31 July 2024	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised cost	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Financial liabilities					
Liabilities to banks	1,059,325	0	0	1,059,325	1,056,955
Bonds	679,731	0	0	679,731	691,784
Loans	251,367	0	0	251,367	251,367
Trade payables	6,420,030	0	0	6,420,030	6,420,030
Liabilities to related parties	20,307	0	0	20,307	20,307
ABS and factoring liabilities	325,607	0	0	325,607	325,607
Other financial liabilities	53,862	1,065	0	54,927	54,927
Lease liabilities	0	0	978,958	978,958	n/a
Derivative financial liabilities without hedge accounting	0	3,117	0	3,117	3,117

31 January 2024	Category pursuant to IFRS 9			Carrying amount	Fair value
	At amortised cost	At fair value through profit and loss	No category according to IFRS 9		
EUR k					
Financial liabilities					
Liabilities to banks	831,164	0	0	831,164	828,390
Bonds	398,481	0	0	398,481	391,500
Loans	212,933	0	0	212,933	212,933
Trade payables	6,520,850	0	0	6,520,850	6,520,850
Liabilities to associates and related parties	24,242	0	0	24,242	24,242
ABS and factoring liabilities	336,752	0	0	336,752	336,752
Other financial liabilities	32,064	1,541	0	33,605	33,605
Lease liabilities	0	0	979,756	979,756	n/a
Derivative financial liabilities without hedge accounting	0	4,215	0	4,215	4,215

The fair value of the bonds is the nominal value multiplied by the quoted price as of the reporting date (level 1).

Derivatives are recognised at their fair values (level 2).

Due to the short-term maturities of trade payables and other current financial liabilities, their carrying amounts generally approximate the fair values at the reporting date (level 2).

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity
[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Fair value hierarchy of financial instruments

PHOENIX applies the following fair value hierarchy to define and present its financial instruments measured at fair value:

Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: Techniques that use inputs that are not based on observable market data.

Financial instruments measured at fair value

EUR k	Level 1	Level 2	Level 3	Total
31 July 2024				
Equity and debt instruments	0	0	70,602	70,602
Trade receivables	0	429,083	0	429,083
Derivative financial assets without hedge accounting	0	2,169	0	2,169
Derivative financial liabilities without hedge accounting	0	3,117	0	3,117
Other financial liabilities	0	0	1,065	1,065
31 January 2024				
Equity and debt instruments	0	0	75,753	75,753
Trade receivables	0	429,334	0	429,334
Derivative financial assets without hedge accounting	0	2,214	0	2,214
Derivative financial liabilities without hedge accounting	0	4,215	0	4,215
Other financial liabilities	0	0	1,541	1,541

The following table shows the reconciliation of the fair value based on level 3.

EUR k	Equity and debt instruments	Other financial liabilities
1 February 2024	75,753	1,541
Purchase	300	0
Sale of shares	0	0
Acquisitions	0	353
Remeasurement (through profit and loss)	0	0
Payments due to acquisitions	0	-829
Other	-5,451	0
31 July 2024	70,602	1,065

Notes to the statement of cash flows

EUR k	31 Jan 2024	31 July 2024
Restricted cash		
Cash and cash equivalents at the end of the period	442,740	521,074
thereof restricted		
due to security deposits	1,899	1,895
due to restrictions placed upon foreign subsidiaries	15,139	27,484

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement of comprehensive income
Consolidated statement of financial position
Consolidated statement of cash flows
Consolidated statement of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

Related party disclosures

In connection with the bond issued in July 2024, related parties hold bond certificates with a nominal volume of EUR 49,900k.

On 21 June 2024, all functional areas that perform tasks for the entire PHOENIX group (“headquarters”) were transferred from PHOENIX Pharmahandel GmbH & Co KG to PHOENIX Pharma SE by way of a spin-off and transfer in accordance with section 123 et seq. German Transformation Act (UmwG) from PHOENIX Pharmahandel GmbH & Co KG to PHOENIX Pharma SE. In this context, PHOENIX Pharma SE withdrew net assets totalling EUR 24,165k from PHOENIX Pharmahandel GmbH & Co KG. The spin-off took place in the relationship between PHOENIX Pharmahandel GmbH & Co KG and PHOENIX Pharma SE with effect from 1 February 2024. For the actions taken by PHOENIX Pharmahandel GmbH & Co KG for the account of PHOENIX Pharma SE between 1 February 2024 and 21 June 2024, PHOENIX Pharmahandel GmbH & Co KG had a compensation claim against PHOENIX Pharma SE in the amount of EUR 48,426k, which was recognised in reserves as a shareholder transaction with no effect on profit or loss. From 21 June 2024, expenses and income relating to the headquarters will no longer be incurred by PHOENIX Pharmahandel GmbH & Co KG, but by PHOENIX Pharma SE.

In May 2024, an amount of EUR 23,615k was distributed to PHOENIX Pharma SE withdrew from the reserves.

Furthermore, the business relationships with related parties presented in the consolidated financial statements as of 31 January 2024 remained essentially unchanged in the first half-year of 2024/25.

Mannheim, 12 September 2024

The Management Board of the unlimited partner
PHOENIX Verwaltungs GmbH

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity

[Notes to the interim condensed consolidated financial statements](#)

Financial calendar 2024/Imprint

FINANCIAL CALENDAR 2024

Please consult our calendar for the most important announcement dates:

19 December Quarterly statement February to October 2024

IMPRINT

Publisher

Maren Holoda
Director Corporate Communications

PHOENIX Pharmahandel GmbH & Co KG
Corporate Communications
Pfungstweidstrasse 10–12
68199 Mannheim
Germany
Phone +49 (0)621 8505 8502
Fax +49 (0)621 8505 8501
media@phoenixgroup.eu
www.phoenixgroup.eu

Investor Relations

Karsten Loges
Director Corporate Finance
and Asset Management
Phone +49 (0)621 8505 741
k.loges@phoenixgroup.eu

Concept, design and realisation

Corporate Communications PHOENIX group
HGB Hamburger Geschäftsberichte
GmbH & Co. KG, Hamburg, Germany

Translation of the German version.
The German version is binding.

The first half-year at a glance

Interim group management report

Business and economic environment
Risks and opportunities
Forecast

Interim condensed consolidated financial statements

Consolidated income statement
Consolidated statement
of comprehensive income
Consolidated statement
of financial position
Consolidated statement of cash flows
Consolidated statement
of changes in equity
Notes to the interim condensed
consolidated financial statements

[Financial calendar 2024/Imprint](#)

